AstraZeneca Shares Jump as COPD Drug Tozorakimab Delivers Positive Results
AstraZeneca’s experimental drug tozorakimab significantly reduced COPD flare-ups in two Phase 3 trials. Promising new hope for millions of patients with chronic lung disease.
Already have an account? Sign in.